Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity

Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health‐related quality of life (HRQoL) than those receiving placebo. The current study exten...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolotkin, R. L., Gabriel Smolarz, B., Meincke, H. H., Fujioka, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813214/
https://www.ncbi.nlm.nih.gov/pubmed/29045079
http://dx.doi.org/10.1111/cob.12226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813214/
https://www.ncbi.nlm.nih.gov/pubmed/29045079
http://dx.doi.org/10.1111/cob.12226

Ejemplares similares